Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Miravant
Company Location: SANTA BARBARA CA 93117
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Macular Degeneration|Choroidal Neovascularization
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2005-001856-19 | P3 |
Terminated |
Macular Degeneration|Choroidal Neovascularization |
2008-04-25 |
|
MRVT-920101-OPH005 | P3 |
Unknown status |
Macular Degeneration|Choroidal Neovascularization |
None |